Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Engagement Manager, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

From Walmart to Amazon to 23andMe, these 11 market scenarios paint a picture of what disruption looks like, both in and out of healthcare.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Chief Strategy Officer, BCBS of Massachusetts
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Purposeful collaboration will help more people understand how their daily decisions dictate their health.

Principal, Oliver Wyman

How pharmaceutical companies can better define, measure, and deliver value to patients.

Principal, Oliver Wyman
Senior Consultant, Health & Life Sciences, Oliver Wyman

Traditional retailers are now getting into the health business. What does it all mean, and where should corporate directors focus next?

Partner, Health & Life Sciences, Oliver Wyman

Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.

Principal, Oliver Wyman Actuarial Consulting
Global Head, Health Services, Oliver Wyman
Principal, Oliver Wyman

An examination of how the astronomically deadly and expensive opioid epidemic has generated significant litigation risk for healthcare businesses.

Coverage and Claims Leader, Marsh Casualty

Insights in your inbox

Subscribe